Skip to main content
. Author manuscript; available in PMC: 2021 Aug 15.
Published in final edited form as: Cancer. 2020 Jun 4;126(16):3788–3799. doi: 10.1002/cncr.32996

Fig. 1. Osimertinib inhibits ERK and Akt with different dynamics (A) and, when combined with MEK or ERK inhibition, synergistically decreases cell survival in NSCLC cell lines harboring mutant EGFR (B and C), but not in those with WT EGFR (D and E).

Fig. 1.

A, The given cell lines were exposed to DMSO and 50 nM (PC-9), 100 nM (HCC827) or 250 nM (H1975 and H1650) osimertinib (Osim), respectively, for the different times as indicated. Western blotting was used to detect different proteins. B-E, The indicated cell lines plated in 96-well plates were exposed to varied concentrations of osimertinib alone, trametinib (Tram) or VRT52271 (VRT) alone or their respective combinations. After 3 days, cell numbers were estimated using the SRB assay. The data are means ± SDs of four replicate determinations. The numbers inside the graphs are CIs for the given combinations.